{
    "id": 2449,
    "fullName": "CBL Q365_E366insSK",
    "impact": "insertion",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "CBL Q365_E366insSK lies within the linker region of the Cbl protein (UniProt.org). Q365_E366insSK results in a loss of E3-ligase activity, leading to activation of FLT3, and is transforming when expressed with FLT3 or KIT (PMID: 20622007).",
            "references": [
                {
                    "id": 3307,
                    "pubMedId": 20622007,
                    "title": "Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20622007"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 867,
        "geneSymbol": "CBL",
        "terms": [
            "CBL",
            "C-CBL",
            "CBL2",
            "FRA11B",
            "NSLL",
            "RNF55"
        ]
    },
    "variant": "Q365_E366insSK",
    "createDate": "10/23/2014",
    "updateDate": "07/22/2015",
    "referenceTranscriptCoordinates": {
        "id": 111420,
        "transcript": "NM_005188",
        "gDna": "chr11:g.119277844_119277845insAGCAAG",
        "cDna": "c.1095_1095+1insAGCAAG",
        "protein": "p.Q365_E366insSK",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 18005,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 32934,
                "profileName": "CBL Q365_E366insSK FLT3 wild-type"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18004,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rydapt (midostaurin) inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 32934,
                "profileName": "CBL Q365_E366insSK FLT3 wild-type"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18003,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xospata (gilteritinib) inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 32934,
                "profileName": "CBL Q365_E366insSK FLT3 wild-type"
            },
            "therapy": {
                "id": 2865,
                "therapyName": "Gilteritinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18001,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Crenolanib inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 32934,
                "profileName": "CBL Q365_E366insSK FLT3 wild-type"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18006,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ayvakit (avapritinib) inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture with reduced potency compared to other kinase inhibitors (PMID: 31309543).",
            "molecularProfile": {
                "id": 32934,
                "profileName": "CBL Q365_E366insSK FLT3 wild-type"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18002,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Quizartinib (AC220) inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 32934,
                "profileName": "CBL Q365_E366insSK FLT3 wild-type"
            },
            "therapy": {
                "id": 882,
                "therapyName": "Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20890,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PRT062607 to treatment with Rydapt (midostaurin) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 9494,
                "therapyName": "Midostaurin + PRT062607",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20892,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PRT062607 to treatment with Quizartinib (AC220) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 9496,
                "therapyName": "PRT062607 + Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20870,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rydapt (midostaurin) inhibited proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture, and inhibited leukemic growth and prolonged survival in cell line xenograft models expressing FLT3 and CBL Q365_E366insSK (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20906,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PRT062607 to treatment with Xospata (gilteritinib) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 9498,
                "therapyName": "Gilteritinib + PRT062607",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20891,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PRT062607 to treatment with Nexavar (sorafenib) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 9495,
                "therapyName": "PRT062607 + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20905,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PRT062607 to treatment with Crenolanib resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 9497,
                "therapyName": "Crenolanib + PRT062607",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20868,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Quizartinib (AC220) inhibited proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 882,
                "therapyName": "Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20865,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20907,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Entospletinib to treatment with Rydapt (midostaurin) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 9499,
                "therapyName": "Entospletinib + Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20867,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Crenolanib inhibited proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20866,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xospata (gilteritinib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 2865,
                "therapyName": "Gilteritinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2331,
            "profileName": "CBL Q365_E366insSK",
            "profileTreatmentApproaches": [
                {
                    "id": 16983,
                    "name": "FLT3 Inhibitor",
                    "profileName": "CBL Q365_E366insSK"
                }
            ]
        },
        {
            "id": 32934,
            "profileName": "CBL Q365_E366insSK FLT3 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35378,
            "profileName": "CBL Q365_E366insSK FLT3 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 111421,
            "transcript": "XM_011543057",
            "gDna": "chr11:g.119277844_119277845insAGCAAG",
            "cDna": "c.1095_1095+1insAGCAAG",
            "protein": "p.Q365_E366insSK",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111420,
            "transcript": "NM_005188",
            "gDna": "chr11:g.119277844_119277845insAGCAAG",
            "cDna": "c.1095_1095+1insAGCAAG",
            "protein": "p.Q365_E366insSK",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}